Oxford BioTherapeutics (OBT) has entered into a multi-year collaboration with Roche to discover and develop novel antibody-based therapies for cancer treatment. Through this partnership, OBT will use its OGAP-Verify discovery platform to identify and validate new therapeutic targets. Roche will lead the further research, development, and commercialization of any resulting treatments. Under the agreement, OBT will receive up to $36 million in upfront payments and may earn milestone payments exceeding $1 billion, along with royalties on future product sales. The collaboration combines OBT’s innovative target discovery approach with Roche’s expertise in drug development to advance new therapies addressing critical needs in oncology.
OBT’s OGAP-Verify platform enhances the identification of promising cancer targets through increased sensitivity and accuracy. The company’s lead clinical program, OBT076, is currently being evaluated in a U.S. clinical trial for patients with advanced solid tumors. OBT has a proven track record in oncology research, supported by collaborations with industry leaders including Boehringer Ingelheim and ImmunoGen. OBT’s management team brings extensive experience in developing immuno-oncology and antibody-based treatments. Through this collaboration, both companies aim to accelerate the discovery of advanced cancer therapies and provide new treatment options for patients facing serious health challenges.
